Press Release: bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath(R) Lung Commercialization

Dow Jones11-07

CyPath(R) Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79% year-to-date

Company advances precision medicine pipeline with new asthma and COPD research, collaboration with Pictor and continued development of topical skin cancer therapeutics

SAN ANTONIO--(BUSINESS WIRE)--November 06, 2026-- 

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics for skin cancer, today reported financial results and business highlights for the third quarter (Q3) ended September 30, 2026.

Q3 2026 Highlights and Recent Events

   --  CyPath(R) Lung test unit sales increased 100% through Q3 compared to 
      the first nine months of 2025. 
 
   --  CyPath Lung testing revenue for the first nine months of 2026 increased 
      79% to approximately $1.1 million, compared to the same period in 2025. 
 
 
   --  In July 2026, the Company surpassed the total number of CyPath Lung 
      test reports delivered to physicians during 2025. 
 
   --  The number of ordering physicians increased by 89% in the third quarter 
      of 2026 compared to the third quarter of 2025, continuing to expand 
      clinical utilization of CyPath Lung. Physicians already ordering CyPath 
      Lung tests increased their volume by 48% year over year. 
 
   --  The Company expanded its government healthcare distribution network and 
      commercial reach through an agreement with AvMEDICAL, a Service-Disabled 
      Veteran-Owned Small Business and established distributor of 
      medical-surgical and laboratory products and services to government 
      agencies, including the Department of Veterans Affairs (VA). 
 
   --  The ongoing longitudinal clinical trial designed to evaluate the 
      clinical performance of CyPath Lung continued to advance. As of September 
      30, 2026, 11 clinical sites were active, including nine VA and military 
      medical centers that had begun patient enrollment. The John P. Murtha 
      Cancer Center Research Program at the Uniformed Services University of 
      the Health Sciences is providing support and funding for the trial. 
 
   --  In July, the Company published a comprehensive clinical review and 
      white paper authored by Chief Medical Officer Gordon H. Downie, MD, PhD, 
      presenting a practical framework for incorporating CyPath Lung into 
      pulmonology and oncology practices. Dr. Downie presented the framework to 
      physicians in October at the annual meeting of the American College of 
      Chest Physicians (CHEST 2026). 
 
   --  The Company advanced CyPath Lung for potential use in surveillance of 
      lung cancer survivors as a complement to imaging to monitor patients for 
      cancer recurrence and new primary lung cancers. 
 
   --  The Company presented positive research results at CHEST 2026 relating 
      to its development of noninvasive tests to characterize lung inflammation 
      and investigate biologic drug targets for asthma and COPD therapies. 
      Further development and validation are underway to determine whether this 
      approach can identify patients who may benefit from specific biologic 
      therapies or support monitoring of lung inflammation over time. 
 
   --  The Company announced a collaboration with Pictor(R), Inc., a targeted 
      proteomic platform company, to support development and potential 
      commercialization of bioAffinity Technologies' next-generation diagnostic 
      tests designed to provide a more complete picture of lung inflammation in 
      patients with asthma and COPD. 
 
   --  The Company continued research into potential topically delivered 
      therapeutics for squamous and basal cell skin cancers. Preliminary 
      research findings have demonstrated that self-delivering, stabilized 
      small interfering RNAs (siRNAs) selectively kill squamous and basal 
      carcinoma cells in vitro while sparing noncancerous cutaneous cells. 
 
   --  In September, bioAffinity announced the grant of a Hong Kong patent 
      covering CyPath Lung's proprietary flow cytometry + AI platform for 
      predicting the likelihood of lung cancer by characterizing cell 
      populations in sputum. In October, the Company received a Notice of 
      Allowance from the Japan Patent Office indicating its intention to grant 
      a patent for the method of predicting the likelihood of lung cancer used 
      by the CyPath Lung test. 
 
   --  The Company raised an aggregate of $8.0 million in gross proceeds 
      through a private placement offering in August 2026 and a registered 
      direct offering and concurrent private placement in October 2026 for 
      working capital and general corporate purposes, including support for the 
      ongoing commercialization of CyPath Lung. 

Management Commentary

"Our third-quarter results reflect CyPath Lung's continued momentum in addressing the critical need for early lung cancer detection, driven by both new physicians ordering the test and increased use by existing customers. We believe this growth reflects increasing physician engagement and recognition of the role CyPath Lung can play in managing care for patients at risk for lung cancer. We are also advancing its potential use in surveillance following curative-intent treatment, where CyPath Lung could complement imaging in monitoring for recurrence and new cancers," said Maria Zannes, President of CEO of bioAffinity Technologies. "Peer-to-peer education and growing clinical experience with the test remain important drivers of adoption, while our longitudinal study is designed to generate robust, real-world data across multiple sites to further evaluate how CyPath Lung may support risk assessment and clinical decision-making. Together, these efforts advance our objective of establishing CyPath Lung as a standard of care for evaluating patients at risk for lung cancer.

"We continue to build the foundation for long-term growth. Beyond lung cancer, we are advancing our platform to take advantage of precision medicine opportunities in asthma and COPD, where sputum-based analysis may help characterize lung inflammation and help physicians better match individual patients to available treatments, including Tezspire, Dupixent and Nucala. The tests we are developing are designed to meet a critical need for precision diagnostics in the multi-billion-dollar asthma and COPD therapeutic markets.

"Our patent portfolio now includes 22 awarded U.S. and foreign patents and 36 pending applications. The recent Hong Kong patent and the Japanese patent allowance, once awarded, are important additions to our patent portfolio. Our distribution agreement with AvMEDICAL is intended to expand our reach into government healthcare markets, including the VA, where the substantial burden of lung cancer underscores the need for more effective ways to evaluate pulmonary nodules and improve patient outcomes.

Ms. Zannes concluded, "Our priorities remain disciplined execution, expanding commercial adoption and advancing our clinical and research programs. We are also pursuing topical therapeutic approaches for squamous and basal cell skin cancers based on promising findings involving the CD320 and LRP2 receptors. We believe our expertise in flow cytometry, automated data analysis and siRNA technology provides a foundation for developing differentiated products across these markets. Together, these programs demonstrate our commitment to translating scientific innovation into meaningful new opportunities for patients and the Company."

Third Quarter 2026 Financial Results

Total revenue for the quarter ended September 30, 2026, was approximately $1.1 million, compared with approximately $1.4 million for the same period in 2025. The decrease is due primarily to a decrease in average reimbursement per CyPath Lung test and a slight decline in total cases completed at Precision Pathology Laboratory Services (PPLS) compared to the same period in 2025, in part due to internal business changes at three PPLS research clients. Multiple accounts previously serviced under these clients have since returned to PPLS. The Company is working to restore additional accounts and improve reimbursement levels.

Net loss for the quarter ended September 30, 2026, was approximately $5.3 million, compared with approximately $5.1 million for the third quarter of 2025. The increase in net loss is primarily due to the increase in loss from operations of approximately $3.5 million from approximately $2.3 million in the prior-year quarter, partially offset by a $1.2 million loss from the change in fair value of warrants, compared with a $2.7 million loss in the prior-year quarter.

Cash and cash equivalents were approximately $2.6 million as of September 30, 2026, compared with approximately $6.4 million at December 31, 2025. Subsequent to quarter-end, the Company completed a financing that generated approximately $4.0 million in gross proceeds.

Operating expenses for the third quarter of 2026 were approximately $4.6 million, compared with approximately $3.7 million in the third quarter of 2025.

   --  Direct costs and expenses were approximately $1.1 million, compared 
      with $942,000 in the prior-year period. The increase primarily reflected 
      additional personnel to process CyPath Lung commercial tests and tests 
      associated with the longitudinal clinical study. 
 
   --  Research and development expenses increased 18% year over year to 
      approximately $389,000, primarily due to laboratory supplies and costs 
      associated with relocating laboratory facilities in June 2026. 
 
   --  Clinical development expenses increased 75% to approximately $251,000, 
      compared with approximately $143,000 in the third quarter of 2025. The 
      increase primarily reflected the initiation of clinical trial sites and 
      patient enrollment in the longitudinal clinical study. 
 
   --  Selling, general and administrative expenses increased 28% to 
      approximately $2.8 million, compared with approximately $2.2 million in 
      the prior-year period. The increase primarily reflected additional sales 
      and marketing personnel and support services to expand commercialization 
      of CyPath Lung. 

About CyPath Lung

CyPath Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung analyzes the lung microenvironment by using advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. The test incorporates a novel fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings. For more information, visit www.cypathlung.com.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments $(CLIA)$, which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" and similar expressions may identify forward-looking statements, although not all forward-looking statements contain these words. Actual results could differ materially from those expressed or implied because of risks and uncertainties, including the Company's ability to expand the commercial adoption of CyPath Lung and capitalize on government healthcare market opportunities; the timing, cost, enrollment and outcome of clinical studies; the possibility that preliminary, in vitro or study-specific findings will not be replicated or translate into safe and effective therapies or commercial products for asthma, COPD or skin cancer; the need for further validation of new applications, including surveillance; the extent and timing of physician adoption, repeat utilization and customer retention; payer coverage, reimbursement rates and collections; and the Company's ability to obtain, maintain and enforce intellectual property rights. Additional risks are discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings, including its reports on Forms 10-Q and 8-K. Forward-looking statements reflect expectations and assumptions only as of the date of this release. Readers should not place undue reliance on them. The Company undertakes no obligation to update these statements, except as required by applicable law.

 
                   bioAffinity Technologies, Inc. 
               Condensed Consolidated Balance Sheets 
 
                                      September 30,   December 31, 
                                           2026            2025 
                                      -------------  --------------- 
                                      (unaudited) 
ASSETS 
Current assets: 
   Cash and cash equivalents          $  2,550,034   $  6,449,782 
   Accounts and other receivables, 
    net                                    742,144        541,962 
   Inventory                               108,754         53,548 
   Prepaid expenses and other 
    current assets                         427,230        519,916 
                                       -----------    ----------- 
      Total current assets               3,828,162      7,565,208 
 
Non-current assets: 
   Property and equipment, net             362,359        265,593 
   Operating lease right-of-use 
    asset, net                             730,572        334,289 
   Finance lease right-of-use asset, 
    net                                    538,326        661,575 
   Goodwill                              1,404,486      1,404,486 
   Intangible assets, net                  673,056        716,806 
   Other assets                             16,710         12,815 
                                       -----------    ----------- 
 
      Total assets                    $  7,553,671   $ 10,960,772 
                                       ===========    =========== 
 
LIABILITIES AND STOCKHOLDERS' 
EQUITY 
 
Current liabilities: 
   Accounts payable                   $    949,018   $    761,901 
   Accrued expenses                      1,143,227      1,717,989 
   Unearned revenue                         48,874         42,405 
   Operating lease liability, 
    current portion                        168,534        139,220 
   Finance lease liability, current 
    portion                                 78,926        139,490 
   Notes payable, current portion          144,715        105,161 
                                       -----------    ----------- 
      Total current liabilities          2,533,294      2,906,166 
 
Non-current liabilities: 
   Operating lease liability, net of 
    current portion                        596,086        202,878 
   Finance lease liability, net of 
    current portion                        475,772        532,759 
   Notes payable, net of current 
    portion                                 33,958         41,313 
                                       -----------    ----------- 
 
      Total liabilities                  3,639,110      3,683,116 
                                       -----------    ----------- 
 
Stockholders' equity: 
   Preferred Stock, par value $0.001 
    per share; 20,000,000 shares 
    authorized; 150 shares and 700 
    shares issued and outstanding at 
    September 30, 2026, and December 
    31, 2025, respectively                       1              1 
   Common Stock, par value $0.007 
    per share; 350,000,000 shares 
    authorized; 1,166,625 and 
    299,826 issued and outstanding 
    at September 30, 2026, and 
    December 31, 2025, respectively          8,166          2,097 
   Additional paid-in capital           84,734,173     75,829,622 
   Accumulated deficit                 (80,827,779)   (68,554,064) 
                                       -----------    ----------- 
 
      Total stockholders' equity         3,914,561      7,277,656 
                                       -----------    ----------- 
 
Total liabilities and stockholders' 
 equity                               $  7,553,671   $ 10,960,772 
                                       ===========    =========== 
 
 
                        bioAffinity Technologies, Inc. 
           Unaudited Condensed Consolidated Statements of Operations 
 
                         Three Months Ended            Nine Months Ended 
                            September 30,                 September 30, 
                     --------------------------  ------------------------------ 
                         2026          2025          2026            2025 
                     ------------  ------------  -------------  --------------- 
 
Net revenue          $ 1,070,280   $ 1,446,066   $  3,932,386   $  4,569,146 
                      ----------    ----------    -----------    ----------- 
 
Operating 
expenses: 
   Direct costs and 
    expenses           1,114,176       942,211      3,130,649      3,326,673 
   Research and 
    development          389,122       330,589      1,100,404      1,009,347 
   Clinical 
    development          251,043       143,311      1,060,968        410,943 
   Selling, general 
    and 
    administrative     2,759,769     2,209,441      8,859,961      6,876,551 
   Depreciation and 
    amortization          66,842       113,360        242,916        381,177 
                      ----------    ----------    -----------    ----------- 
 
      Total 
       operating 
       expenses        4,580,952     3,738,912     14,394,898     12,004,691 
                      ----------    ----------    -----------    ----------- 
 
Loss from 
 operations           (3,510,672)   (2,292,846)   (10,462,512)    (7,435,545) 
                      ----------    ----------    -----------    ----------- 
 
Other income 
(expense): 
   Interest income         4,734         1,088         18,118          3,655 
   Interest expense      (10,713)       (5,358)       (37,123)       (31,303) 
   Other income            3,144           513          6,516         38,568 
   Other expense         (13,072)       (3,839)       (48,270)       (16,828) 
   Offering costs 
    allocated to 
    warrant 
    liability           (532,209)           --       (532,209)      (479,696 
   Loss on warrant 
    liabilities       (1,218,235)   (2,747,460)    (1,218,235)    (3,810,278) 
                      ----------    ----------    -----------    ----------- 
 
      Total other 
       income 
       (expense), 
       net            (1,766,351)   (2,755,056)    (1,811,203)    (4,295,882) 
                      ----------    ----------    -----------    ----------- 
 
Net loss before 
 provision for 
 income tax 
 expense              (5,277,023)   (5,047,902)   (12,273,715)   (11,731,427) 
 
Income tax expense            --         3,182             --         40,861 
                      ----------    ----------    -----------    ----------- 
 
Net loss             $(5,277,023)  $(5,051,084)  $(12,273,715)  $(11,772,288) 
                      ==========    ==========    ===========    =========== 
 
Net loss per common 
 share, basic and 
 diluted             $     (5.89)  $    (71.05)  $     (23.72)  $    (219.47) 
 
Weighted average 
 common shares 
 outstanding             896,271        71,090        517,490         53,640 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261106489581/en/

 
    CONTACT:    bioAffinity Technologies 

Julie Anne Overton

Director of Communications

investors@bioaffinitytech.com

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment